aGvHD: Looking at a 2-6 month approval (priority review) and if successful launch early next year. Looking at a confirmatory study in high risk adults (targeting 50% of the adult market).
ARDS: Wish to replicate results for younger COVID patients; plus other causes of ARDS such as influenza and bacterial pneumonia.
- Forums
- ASX - By Stock
- Ann: MSB Q3 Financial Results and Operational Highlights
aGvHD: Looking at a 2-6 month approval (priority review) and if...
-
- There are more pages in this discussion • 154 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
98.0¢ |
Change
-0.010(1.01%) |
Mkt cap ! $1.118B |
Open | High | Low | Value | Volume |
$1.00 | $1.01 | 98.0¢ | $4.720M | 4.751M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
10 | 171759 | 98.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
99.0¢ | 16000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
10 | 171759 | 0.980 |
6 | 123454 | 0.975 |
9 | 228392 | 0.970 |
6 | 122208 | 0.965 |
10 | 79500 | 0.960 |
Price($) | Vol. | No. |
---|---|---|
0.990 | 16000 | 1 |
0.995 | 62678 | 2 |
1.000 | 70444 | 6 |
1.005 | 27224 | 1 |
1.010 | 48336 | 6 |
Last trade - 16.10pm 25/06/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |